Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.61 |
| ▸ | CA2 | P00918 | 13/20 | 0.61 |
| ▸ | CA12 | O43570 | 7/20 | 0.61 |
| ▸ | CA9 | Q16790 | 7/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10191081 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040473 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040417 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL29040410 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL4640090 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL16930099 | 1.00 | CA1 (0.61) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL2822013 | 0.99 | CA1 (0.60) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL487585 | 0.95 | CA1 (0.59) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL17162051 | 0.94 | CA1 (0.55) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL22326309 | 0.92 | CA1 (0.56) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403646-B2 | Method for 3D printing with a bio-ink | FIDIA FARMACEUTICI S.P.A. (IT) | 2025-09-02 | — | — | US | disclosed |
| EP-4121464-B1 | A BIO-INK FOR 3D PRINTING, RELATED CONJUGATE AND PREPARATION PROCESS OF AN INTERMEDIATE CONSISTING OF A PHOTOREACTIVE LINKER | FIDIA FARM SPA (IT) | 2025-01-01 | — | — | EP | disclosed |
| US-20240217166-A1 | A BIO-INK FOR 3D PRINTING, RELATED CONJUGATE AND PREPARATION PROCESS OF AN INTERMEDIATE CONSISTING OF A PHOTOREACTIVE LINKER | FIDIA FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| CN-115244087-B | Method for preparing bio-ink for 3D printing, related conjugate and intermediate composed of photoreactive linker | 费迪亚医药股份公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4121464-A1 | A BIO-INK FOR 3D PRINTING, RELATED CONJUGATE AND PREPARATION PROCESS OF AN INTERMEDIATE CONSISTING OF A PHOTOREACTIVE LINKER | Fidia Farmaceutici S.p.A. (IT) | 2023-01-25 | — | — | EP | disclosed |
| CN-115244087-A | Method for preparing bio-ink for 3D printing, related conjugates and intermediates consisting of photoreactive linker | 费迪亚医药股份公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2021186335-A1 | A BIO-INK FOR 3D PRINTING, RELATED CONJUGATE AND PREPARATION PROCESS OF AN INTERMEDIATE CONSISTING OF A PHOTOREACTIVE LINKER | FIDIA FARMACEUTICI S.P.A. (IT) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403646-B2 | Method for 3D printing with a bio-ink | BTD, HTR3D, UGT1A3 | CA1 2762/4885CA2 4248/4885CA12 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.